* Dipyridamole inhibits the [[phosphodiesterase]] enzymes that normally break down [[Cyclic adenosine monophosphate|cAMP]] (increasing cellular cAMP levels and blocking the [[platelet aggregation]] response<ref name=Brown2015>{{cite journal|vauthors=Brown DG, Wilkerson EC, Love WE | title=A review of traditional and novel oral anticoagulant and antiplatelet therapy for dermatologists and dermatologic surgeons|journal=Journal of the American Academy of Dermatology|volume=72|issue=3|pages=524â€“34|date=March 2015|pmid=25486915|doi= 10.1016/j.jaad.2014.10.027}}</ref>  to [[Adenosine diphosphate|ADP]]) and/or [[cyclic guanosine monophosphate|cGMP]].

 
* It inhibits the cellular reuptake of [[adenosine]] into [[platelets]], [[red blood cell]]s, and [[endothelial cell]]s leading to increased extracellular concentrations of adenosine.

 

